abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

Comparison of Biologic Discontinuation in Patients With Elderly-Onset Versus Younger-Onset Rheumatoid Arthritis

Author

ACR Open Rheumatol. 2019 Oct 26;1(10):627-631. doi: 10.1002/acr2.11083.eCollection 2019 Dec.

Michael D Richter 1, Eric L Matteson 1, John M Davis 3rd 1, Sara J Achenbach 1, Cynthia S Crowson 1

Author Information

  • 1Mayo Clinic College of Medicine and Science, Rochester, Minnesota.

Abstract

Objective: The objective of this study is to compare biologic drug discontinuation rates for older- versus younger-onset rheumatoid arthritis (YORA) because this is a key outcome measure that could impact prescribing practices.

Methods: We performed a retrospective medical record review of all patients who fulfilled the 1987 American College of Rheumatology (ACR) criteria for adult-onset rheumatoid arthritis (RA) in 1999-2013 among residents of a geographically defined area, with follow-up until death, migration, or July 1, 2017. Discontinuation rates were estimated using cumulative incidence adjusted for the competing risk of death.

Results: A total of 240 cases of elderly-onset rheumatoid arthritis (EORA) and 366 cases of YORA were identified (65% and 73% female, respectively; P = 0.025). Cumulative incidence of biologic initiation was lower among the EORA cohort compared with the YORA cohort (18% vs 33%, respectively, at 10 years after RA incidence; P < 0.001). Among those treated with a biologic, years from RA diagnosis to first biologic treatment was not significantly different between the two groups (P = 0.62). Drug survival of first biologic was 64% at 1 year (95% confidence interval [CI]: 45%-77%) and 53% at 2 years (95% CI: 33%-66%) for EORA, compared with 61% at 1 year (95% CI: 50%-69%) and 45% at 2 years (95% CI: 34%-53%) for YORA (P = 0.75). Concurrent glucocorticoid use at initiation of first biologic was statistically and significantly associated with a lower risk of discontinuation in EORA (hazard ratio 0.21; 95% CI: 0.08-0.53) but not in YORA (interaction P = 0.04).

Conclusion: Drug survival rates of biologic medications did not differ significantly between patients with EORA and YORA.